MD4369B1 - Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei - Google Patents

Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei

Info

Publication number
MD4369B1
MD4369B1 MDA20130069A MD20130069A MD4369B1 MD 4369 B1 MD4369 B1 MD 4369B1 MD A20130069 A MDA20130069 A MD A20130069A MD 20130069 A MD20130069 A MD 20130069A MD 4369 B1 MD4369 B1 MD 4369B1
Authority
MD
Moldova
Prior art keywords
tachycardia
glycopyrrolate
prophylaxis
treatment
delivery device
Prior art date
Application number
MDA20130069A
Other languages
English (en)
Russian (ru)
Other versions
MD20130069A2 (ro
MD4369C1 (ro
Inventor
Susan Snape
Robert Tansley
Original Assignee
Sosei R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4369(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103770.2A external-priority patent/GB201103770D0/en
Priority claimed from GBGB1202256.2A external-priority patent/GB201202256D0/en
Application filed by Sosei R&D Ltd filed Critical Sosei R&D Ltd
Publication of MD20130069A2 publication Critical patent/MD20130069A2/ro
Publication of MD4369B1 publication Critical patent/MD4369B1/ro
Publication of MD4369C1 publication Critical patent/MD4369C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)

Abstract

Invenţia se referă la medicină, în special la utilizarea glicopirolatului pentru tratarea tahicardiei, un dispozitiv de administrare, o metodă de tratament şi profilaxie a tahicardiei asociată cu alte patologii, cum ar fi: bronhopneumopatia obstructivă cronică, astmul bronşic, fibroza chistică şi alte boli ale căilor respiratorii.Conform invenţiei, se revendică utilizarea unei compoziţii farmaceutice inhalabile cu conţinut de glicopirolat sau de o sare farmaceutic acceptabilă a acestuia în calitate de agent de reducere a frecvenţei contracţiilor cardiace.
MDA20130069A 2011-03-04 2012-03-05 Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei MD4369C1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1103770.2A GB201103770D0 (en) 2011-03-04 2011-03-04 Novel use
GBGB1202256.2A GB201202256D0 (en) 2012-02-09 2012-02-09 Novel use
PCT/GB2012/050478 WO2012120284A1 (en) 2011-03-04 2012-03-05 Use of glycopyrrolate for treating tachycardia

Publications (3)

Publication Number Publication Date
MD20130069A2 MD20130069A2 (ro) 2014-03-31
MD4369B1 true MD4369B1 (ro) 2015-09-30
MD4369C1 MD4369C1 (ro) 2016-04-30

Family

ID=45841526

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20130069A MD4369C1 (ro) 2011-03-04 2012-03-05 Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei

Country Status (20)

Country Link
US (2) US20140080890A1 (ro)
EP (1) EP2680841B1 (ro)
JP (1) JP6129081B2 (ro)
KR (1) KR101853997B1 (ro)
CN (1) CN103501781B (ro)
AR (1) AR085616A1 (ro)
AU (1) AU2012226608B2 (ro)
BR (1) BR112013022523A2 (ro)
CA (1) CA2828640C (ro)
CL (1) CL2013002542A1 (ro)
EA (1) EA025287B1 (ro)
ES (1) ES2613754T3 (ro)
GE (1) GEP201706640B (ro)
IL (1) IL227972A (ro)
JO (1) JO3510B1 (ro)
MD (1) MD4369C1 (ro)
MX (1) MX356025B (ro)
TW (1) TWI536988B (ro)
WO (1) WO2012120284A1 (ro)
ZA (1) ZA201306130B (ro)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2010138862A2 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
AU2013100009B4 (en) * 2013-01-04 2013-03-14 Novartis Ag Treatment of chronic obstructive pulmonary disease
MX361286B (es) * 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
DK3191081T3 (da) 2014-09-09 2020-06-15 Vectura Ltd Formulering, som omfatter glycopyrrolat, fremgangsmåde og indretning
WO2016071862A1 (en) * 2014-11-05 2016-05-12 Glenmark Pharmaceuticals Limited Inhalable pharmaceutical composition comprising glycopyrronium
ES2794775T3 (es) 2015-09-09 2020-11-19 Vectura Ltd Procedimiento de molienda por chorro
EP3248646B1 (de) * 2016-05-25 2021-02-17 Claudia Mattern Zweiteiliges kunststoffrohling-set
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
WO2018167180A1 (en) * 2017-03-15 2018-09-20 Vectura Limited Method and formulation
KR102669919B1 (ko) * 2019-07-10 2024-05-28 한미약품 주식회사 흡입용 캡슐제 및 이의 제조방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
BE718438A (ro) * 1967-08-23 1968-12-31
NL8104929A (nl) * 1980-11-12 1982-06-01 Alza Corp Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan.
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP0909163A4 (en) * 1996-07-01 1999-06-09 Sepracor Inc METHOD AND MEANS FOR TREATING URINE INCONTINENCE USING THE (S, R) -GLYCOPYRROLATE ENANTIOMER MAINLY
GB9808470D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
KR20000013487A (ko) * 1998-08-10 2000-03-06 정주영 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물
EP1131059B1 (de) 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE10136404A1 (de) * 2001-07-26 2003-02-20 Johannes Wohlrab Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
PL1718336T3 (pl) * 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Nowe połączenie środków antycholinergicznych i beta-mimetyków do leczenia chorób układu oddechowego
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
US7923455B2 (en) 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
GB0703999D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2010144628A2 (en) 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration

Also Published As

Publication number Publication date
KR20140020950A (ko) 2014-02-19
IL227972A (en) 2017-06-29
ZA201306130B (en) 2014-04-30
EP2680841B1 (en) 2016-12-28
AU2012226608B2 (en) 2015-11-26
BR112013022523A2 (pt) 2016-11-29
TWI536988B (zh) 2016-06-11
IL227972A0 (en) 2013-09-30
ES2613754T3 (es) 2017-05-25
MD20130069A2 (ro) 2014-03-31
CN103501781A (zh) 2014-01-08
EA201391275A1 (ru) 2014-02-28
GEP201706640B (en) 2017-03-27
TW201247198A (en) 2012-12-01
KR101853997B1 (ko) 2018-05-02
EP2680841A1 (en) 2014-01-08
CA2828640A1 (en) 2012-09-13
MX2013009838A (es) 2016-09-27
US20160143880A1 (en) 2016-05-26
MD4369C1 (ro) 2016-04-30
EA025287B1 (ru) 2016-12-30
JP6129081B2 (ja) 2017-05-17
WO2012120284A1 (en) 2012-09-13
US10695321B2 (en) 2020-06-30
JO3510B1 (ar) 2020-07-05
JP2014514271A (ja) 2014-06-19
AU2012226608A1 (en) 2013-09-12
NZ614603A (en) 2016-01-29
AR085616A1 (es) 2013-10-16
MX356025B (es) 2018-05-09
US20140080890A1 (en) 2014-03-20
CL2013002542A1 (es) 2014-07-11
CN103501781B (zh) 2016-10-26
CA2828640C (en) 2017-01-03

Similar Documents

Publication Publication Date Title
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
EP2749277A3 (en) Combination of glycopyrronium and vilanterol
PH12016501439A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
CA2897464C (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
NZ587561A (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
WO2009019598A3 (en) Inhalation therapy for respiratory disorders
MX357556B (es) Composiciones acuosas que comprenden arbekacina.
MY179794A (en) Compound composition for inhalation used for treating asthma
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
EP2442657A4 (en) USE OF R-BAMBUTEROL AS INHALED MEDICAMENT AND COMBINATION THERAPIES FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
JP2013522295A5 (ro)
IN2014MN02133A (ro)
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
EP2763687A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC SYNDROME, OBSTRUCTIVE RESPIRATORY DISORDERS, CANCER AND RELATED DISEASES
MX2014001940A (es) Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal.
MY171271A (en) Method for preparing metered dose sprayed inhaler for treating respiratory disease
UA93957U (uk) Спосіб профілактики респіраторних ускладнень у хворих на хронічне обструктивне захворювання легень після операції на легенях і плеврі
AR098868A1 (es) Composición farmacéutica en polvo seco para inhalación
UA98831C2 (ru) Способ лечения бронхиальной астмы с сопутствующим диспептическим синдромом
NZ712403A (en) Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration

Legal Events

Date Code Title Description
FG4A Patent for invention issued
TH4A Change/correction in patent specification

Free format text: CHANGE/CORRECTION IN INID 73

PD4A Change of proprietorship (patent for invention)

Owner name: HEPTARES THERAPEUTICS LIMITED, GB STR. GRANTA PARK

Free format text: PREVIOUS PROPRIETOR: SOSEI R&D LTD, GB STR. NORTH WEST HOUSE, 119 MARYLEBONE ROAD, LONDON, NW1 5PU, ENGLAND, MAREA BRITANIE

TC4A Change of name of proprietor (patent for invention)

Owner name: NXERA PHARMA UK LIMITED, GB GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CAMBRIDGESHIRE, CB21 6DG, MAREA BRITANIE

Free format text: PREVIOUS NAME OF PROPRIETOR: HEPTARES THERAPEUTICS LIMITED, GB STR. GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, CAMBRIDGESHIRE, CB21 6DG, MAREA BRITANIE